Gilead Gets CHMP Nod for New HIV Combo

Gilead has received the green light in the EU for marketing its newest fixed-dose HIV treatment Odefsey but its cannibalization of predecessor product Complera will not reach levels expected in the US as generic versions of older HIV combos are set to arrive earlier in the EU.

The EU's CHMP has given Gilead Sciences Inc. the go-ahead for marketing of its new fixed-dose combination HIV treatment Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg; R/F/TAF).

The product is fixed-dose combination of 200 mg of Gilead's emtricitabine, 25 mg of its tenofovir alafenamide with 25 mg...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category